BioStem Technologies (BSEM) announced that the United States Patent and Trademark Office, or USPTO, has issued notices of allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSEM:
- BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright
- BioStem Technologies (BSEM) Q1 Earnings Cheat Sheet
- Biostem Technologies initiated with a Buy at H.C. Wainwright
- BioStem Technologies Balances Bold Acquisition With Strain
- BSEM Earnings Report this Week: Is It a Buy, Ahead of Earnings?